Tencent-backed US drug discovery firm Atomwise closes $123m Series B round

Tencent-backed US drug discovery firm Atomwise closes $123m Series B round

Atomwise, which uses artificial intelligence for structure-based small molecule drug discovery, has raised $123 million in an oversubscribed Series B round, according to a company statement on Tuesday. The San Francisco-based firm said it will use the proceeds to scale and build its own pipeline of experimental drugs.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter